サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1606413

子宮内膜がん市場：がんの種類別、治療の種類別、診断方法別、国別、地域別 - 産業分析、市場規模、市場シェア、予測、2024年～2032年

Endometrial Cancer Market, By Type of Cancer, By Type of Therapy, By Diagnosis Method, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 303 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
子宮内膜がん市場：がんの種類別、治療の種類別、診断方法別、国別、地域別 - 産業分析、市場規模、市場シェア、予測、2024年～2032年
出版日: 2024年11月04日
発行: AnalystView Market Insights
ページ情報: 英文 303 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

子宮内膜がん市場規模は2023年に263億9,453万米ドルとなり、2024年から2032年にかけてCAGR 5.80％で拡大

子宮内膜がん市場-市場力学

子宮内膜がんの有病率の増加が市場拡大を促進すると予測されます。

子宮内膜がんの症例数が増加するにつれて、効率的な診断ツールやサービスに対する需要が高まっています。これには、生検手順とともに超音波やMRIなどの画像技術の利用が含まれます。認知度の向上とスクリーニングの実施により、治療成績の向上に不可欠な早期診断が促進されます。世界がん研究基金インターナショナルによると、2022年に報告された子宮内膜がんの新規症例数は420,368例でした。現在進行中の研究開発は、治療方法の進歩とともに、市場に成長機会をもたらす可能性があります。しかし、ヘルスケアサービスへのアクセスが限られていることが市場成長の妨げになる可能性があります。

子宮内膜がん市場-主要インサイト

当社のリサーチアナリストが共有した分析によると、世界市場は予測期間（2024-2032年）に約5.80%のCAGRで毎年成長すると推定されます。

がんの種類別セグメントでは、子宮内膜がんが2023年に最大の市場シェアを示すと予測されています。

治療の種類別では、2023年に化学療法が主要な種類となった。

診断方法別では、2023年には生検が主要タイプでした。

地域別では、北米が2023年の主要収益源でした。

子宮内膜がん市場-セグメンテーション分析：

世界の子宮内膜がん市場は、がんの種類、治療法の種類、診断方法、地域に基づいて区分されます。

市場はがんのタイプに基づいて2つのカテゴリーに分けられる：子宮内膜がん、子宮肉腫、その他です。子宮内膜がんが市場を独占しています。子宮内膜がんは、子宮の内膜（子宮内膜）に発生するがんの一種です。子宮体がんの大部分を占め、通常閉経後の女性で診断されます。

市場は治療の種類によって3つのセグメントに分類される：免疫療法、放射線療法、化学療法、その他です。免疫療法、放射線療法、化学療法、その他です。化学療法は、進行性、再発性、または侵攻性のタイプの子宮内膜がんに対する主要な治療法の1つとして広く認知されています。

市場は診断法によって4つのカテゴリーに区分される：生検、骨盤超音波検査、子宮鏡検査、CTスキャン、その他です。市場では生検が優位な地位を占めています。子宮内膜がんの早期発見と診断における生検の意義は最も重要であり、治療法の選択と診断ツールや手法の需要に直接影響するからです。

子宮内膜がん市場-地理的洞察

主に診断手法の進歩により、北米が市場をリードしています。この地域は、最先端の診断技術を備えた数多くの確立されたがん治療センターや専門施設を含む強力なヘルスケアシステムを特徴としています。このようなインフラは、診断と治療の両方を含む、がん治療への総合的なアプローチを容易にしています。毎年、約40万人の患者がNCI指定のがんセンターでがんと診断されています。欧州は、意識の高まりと検診プログラムの実施により、市場成長率第2位の地域となっています。世界市場は、認知度、診断能力、治療選択肢が各地域で強化され続けるにつれて、さらに成長すると予想されます。

子宮内膜がん市場-競合情勢：

子宮内膜がん市場は、診断法、治療法、患者の予後改善に焦点を当てた新技術の革新に後押しされ、高いレベルの競合を示します。生検機器、化学療法薬、標的治療薬、免疫療法などの分野で数多くの企業が市場シェアを争っています。免疫療法、標的療法、併用療法など、新たな治療選択肢を生み出すために、研究開発への多額の投資が行われています。リキッドバイオプシーや遺伝子検査などの治療は、早期発見や個別化治療戦略の可能性がますます認められてきています。規制当局の承認プロセスを効率的に進めることができる企業は、特に免疫療法のような急速に発展している分野で競争優位に立つことができます。

目次

第1章 子宮内膜がん市場概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 子宮内膜がんの主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 子宮内膜がん産業研究

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 子宮内膜がん市場： COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19後の影響分析

第6章 子宮内膜がんの市場情勢

  • 子宮内膜がんの市場シェア分析、2023年
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 子宮内膜がん市場- がんの種類別

  • 概要
    • セグメントシェア分析
    • 子宮内膜がん
    • 子宮肉腫
    • その他

第8章 子宮内膜がん市場- 治療の種類別

  • 概要
    • セグメントシェア分析
    • 免疫療法
    • 放射線治療
    • 化学療法
    • その他

第9章 子宮内膜がん市場- 診断方法別

  • 概要
    • セグメントシェア分析
    • 生検
    • 骨盤超音波検査
    • 子宮鏡検査
    • CTスキャン
    • その他

第10章 子宮内膜がん市場-地域

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋地域
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東およびアフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第11章 主要ベンダー分析- 子宮内膜がん業界

  • 競合ダッシュボード
  • 企業プロファイル
    • Pfizer Inc.
    • Bristol Myers Squibb Company
    • Merck &Co. Inc.
    • Novartis International AG
    • AstraZeneca PLC
    • Genentech Inc.（Roche）
    • GlaxoSmithKline PLC
    • Johnson &Johnson
    • Eli Lilly and Company
    • AbbVie Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Bayer AG
    • Sanofi SA
    • Hoffmann-La Roche Ltd.
    • Exelixis Inc.
    • Others

第12章 アナリストの全方位展望

目次
Product Code: ANV4183

REPORT HIGHLIGHT

Endometrial Cancer Market size was valued at USD 26,394.53 million in 2023, expanding at a CAGR of 5.80% from 2024 to 2032.

Endometrial cancer is a form of cancer that originates from the cellular growth within the uterus, which is the hollow, pear-shaped organ in the pelvis responsible for fetal development. In the United States, it is the most prevalent cancer impacting the reproductive system of women and individuals assigned female at birth (AFAB). This type of cancer predominantly occurs following menopause. Approximately 3% of women and individuals with AFAB will be diagnosed with uterine cancer at some stage in their lives, with around 65,000 new cases reported annually.

Endometrial Cancer Market- Market Dynamics

The increasing prevalence of endometrial cancer is anticipated to propel market expansion.

As the number of endometrial cancer cases escalates, there is an increasing demand for efficient diagnostic tools and services. This encompasses the utilization of imaging technologies, such as ultrasound and MRI, along with biopsy procedures. Improved awareness and screening practices can facilitate earlier diagnoses, which are crucial for enhancing treatment outcomes. According to the World Cancer Research Fund International, there were 420,368 new cases of endometrial cancer reported in 2022. The ongoing research and development, along with advancements in treatment modalities, may present growth opportunities for the market. However, limited access to healthcare services could hinder market growth.

Endometrial Cancer Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.80% over the forecast period (2024-2032)

Based on Type of Cancer segmentation, Endometrial Carcinoma was predicted to show maximum market share in the year 2023

Based on Type of Therapy segmentation, Chemotherapy was the leading type in 2023

Based on Diagnosis Method segmentation, Biopsy was the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

Endometrial Cancer Market- Segmentation Analysis:

The Global Endometrial Cancer Market is segmented on the basis of Type of Cancer, Type of Therapy, Diagnosis Method, and Region.

The market is divided into two categories based on the Type of Cancer: Endometrial Carcinoma, Uterine Sarcomas, and Others. Endometrial Carcinoma dominates the market. Endometrial carcinoma is a type of cancer that originates in the lining of the uterus (endometrium). It accounts for the majority of uterine cancers and is usually diagnosed in postmenopausal women.

The market is classified into three segments according to the Type of Therapy: Immunotherapy, Radiation Therapy, Chemotherapy, and Others. The Chemotherapy segment holds a dominant position within the market. It is widely recognized as one of the primary treatment options for advanced, recurrent, or aggressive types of endometrial cancer.

The market is segmented into four categories according to the Diagnosis Method: Biopsy, Pelvic Ultrasound, Hysteroscopy, CT scan, and others. Biopsy holds a predominant position in the market. The significance of biopsies in the early detection and diagnosis of endometrial cancer is paramount, as they directly affect treatment choices and the demand for diagnostic tools and methodologies.

Endometrial Cancer Market- Geographical Insights

North America leads the market, primarily due to advancements in diagnostic methodologies. The region is characterized by a strong healthcare system that includes numerous established cancer treatment centers and specialized facilities, all equipped with cutting-edge diagnostic technologies. This infrastructure facilitates a holistic approach to cancer care, encompassing both diagnosis and treatment. Annually, around 400,000 patients are diagnosed with cancer at NCI-Designated Cancer Centers. Europe ranks as the second largest region for market growth, attributed to heightened awareness and the implementation of screening programs. The global market is anticipated to grow further as awareness, diagnostic capabilities, and treatment alternatives continue to enhance across various regions.

Endometrial Cancer Market- Competitive Landscape:

The Endometrial Cancer Market exhibits a high level of competition, propelled by innovations in diagnostics, treatment modalities, and emerging technologies focused on enhancing patient outcomes. Numerous firms are competing for market share in sectors such as biopsy instruments, chemotherapeutic drugs, targeted therapies, and immunotherapies. Significant investments in research and development are being made to create novel treatment options, including immunotherapies, targeted therapies, and combination approaches. Advancements such as liquid biopsy and genetic testing are increasingly recognized for their potential in early detection and personalized treatment strategies. Companies that can efficiently navigate the regulatory approval process are positioned to gain a competitive edge, particularly in rapidly evolving areas like immunotherapy.

Recent Developments:

On February 5, 2024, Novartis announced that it has reached an agreement to initiate a voluntary public takeover bid for MorphoSys AG, a biopharmaceutical company based in Germany that specializes in the development of innovative oncology treatments.

A recent trial of an innovative antibody drug, which administers powerful chemotherapy directly to cancer cells, is progressing to a phase III study for patients suffering from advanced or recurrent endometrial cancer.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ENDOMETRIAL CANCER MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Pfizer Inc.
  • Bristol Myers Squibb Company
  • Merck & Co. Inc.
  • Novartis International AG
  • AstraZeneca PLC
  • Genentech Inc. (Roche)
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Eli Lilly and Company
  • AbbVie Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG
  • Sanofi S.A.
  • Hoffmann-La Roche Ltd.
  • Exelixis Inc.
  • Others

GLOBAL ENDOMETRIAL CANCER MARKET, BY TYPE OF CANCER- MARKET ANALYSIS, 2019 - 2032

  • Endometrial Carcinoma
  • Uterine Sarcomas
  • Others

GLOBAL ENDOMETRIAL CANCER MARKET, BY TYPE OF THERAPY- MARKET ANALYSIS, 2019 - 2032

  • Immunotherapy
  • Radiation Therapy
  • Chemotherapy
  • Others

GLOBAL ENDOMETRIAL CANCER MARKET, BY DIAGNOSIS METHOD- MARKET ANALYSIS, 2019 - 2032

  • Biopsy
  • Pelvic Ultrasound
  • Hysteroscopy
  • CT scan
  • Others

GLOBAL ENDOMETRIAL CANCER MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Endometrial Cancer Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Endometrial Cancer Market Snippet by Type of Cancer
    • 2.1.2. Endometrial Cancer Market Snippet by Type of Therapy
    • 2.1.3. Endometrial Cancer Market Snippet by Diagnosis Method
    • 2.1.4. Endometrial Cancer Market Snippet by Country
    • 2.1.5. Endometrial Cancer Market Snippet by Region
  • 2.2. Competitive Insights

3. Endometrial Cancer Key Market Trends

  • 3.1. Endometrial Cancer Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Endometrial Cancer Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Endometrial Cancer Market Opportunities
  • 3.4. Endometrial Cancer Market Future Trends

4. Endometrial Cancer Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Endometrial Cancer Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Endometrial Cancer Market Landscape

  • 6.1. Endometrial Cancer Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Endometrial Cancer Market - By Type of Cancer

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type of Cancer, 2023 & 2032 (%)
    • 7.1.2. Endometrial Carcinoma
    • 7.1.3. Uterine Sarcomas
    • 7.1.4. Others

8. Endometrial Cancer Market - By Type of Therapy

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Type of Therapy, 2023 & 2032 (%)
    • 8.1.2. Immunotherapy
    • 8.1.3. Radiation Therapy
    • 8.1.4. Chemotherapy
    • 8.1.5. Others

9. Endometrial Cancer Market - By Diagnosis Method

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Diagnosis Method, 2023 & 2032 (%)
    • 9.1.2. Biopsy
    • 9.1.3. Pelvic Ultrasound
    • 9.1.4. Hysteroscopy
    • 9.1.5. CT scan
    • 9.1.6. Others

10. Endometrial Cancer Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Endometrial Cancer Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Endometrial Cancer Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Endometrial Cancer Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Endometrial Cancer Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Endometrial Cancer Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Type of Cancer, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Type of Therapy, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Diagnosis Method, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Endometrial Cancer Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Pfizer Inc.
    • 11.2.2. Bristol Myers Squibb Company
    • 11.2.3. Merck & Co. Inc.
    • 11.2.4. Novartis International AG
    • 11.2.5. AstraZeneca PLC
    • 11.2.6. Genentech Inc. (Roche)
    • 11.2.7. GlaxoSmithKline PLC
    • 11.2.8. Johnson & Johnson
    • 11.2.9. Eli Lilly and Company
    • 11.2.10. AbbVie Inc.
    • 11.2.11. Teva Pharmaceutical Industries Ltd.
    • 11.2.12. Bayer AG
    • 11.2.13. Sanofi S.A.
    • 11.2.14. Hoffmann-La Roche Ltd.
    • 11.2.15. Exelixis Inc.
    • 11.2.16. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us